Notice of Intent to Sole Source – LabCorp
ID: 26-000086Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/f4ff33b7c9ee45839d268ddb9ccd261f/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Laboratory Corporation of America (LabCorp) for laboratory testing services at the NIH Clinical Center's Department of Pediatrics. The primary objective of this procurement is to measure 11-oxo-androgens, which are critical biomarkers for adrenal disorders, as LabCorp is the only laboratory capable of providing this specific testing panel. This acquisition is vital for maintaining the integrity of ongoing clinical research protocols, particularly for genetic testing related to congenital adrenal hyperplasia (CAH), which has been conducted with LabCorp since 2004. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by January 5, 2026, at 12 PM EST, although the government retains discretion over the decision to compete the requirement.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source – LabCorp
    Currently viewing
    Special Notice
    Similar Opportunities
    Notice of Intent to Sole Source – Werfen USA, LLC
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), intends to award a sole source contract to Werfen USA, LLC for the procurement of kits and reagents essential for patient care testing, specifically for use with the ACL TOP 350 and 750 analyzers. This procurement, valued at approximately $570,000 over a base year and two option years (January 1, 2026, to December 31, 2028), is critical as the reagents are uniquely validated for the existing instruments, ensuring continuity in patient care and research protocols. The acquisition will be conducted under the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for increased procedural flexibility and efficiency. Interested parties may submit comments regarding this notice to Ryssa Nix at ryssa.nix@nih.gov by the close date of December 23, 2025, at 12 PM EST.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), has issued a Special Notice regarding subcontracting opportunities at the Frederick National Laboratory for Cancer Research (FNLCR). This opportunity focuses on the need for laboratory assays and services to assess cytokines in nasal mucosa samples for up to nine phase 1 trials and two phase 2 trials related to the NextGen COVID-19 vaccine program, which is critical for advancing the National Institute of Allergy and Infectious Diseases (NIAID) mission. The FNLCR, operated by Leidos Biomedical Research, Inc., plays a vital role in cancer and AIDS research, and this notice aims to inform potential subcontractors of the requirements without constituting a formal solicitation. Interested parties can reach out to Tara Phillips at tara.phillips@nih.gov for further details regarding Solicitation/RFP No. S26-111, with a response date set for January 14, 2026.
    Notice of Intent to Sole Source Modification of Contract to Quest Diagnostics, Inc.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), intends to negotiate a non-competitive modification to an existing contract with Quest Diagnostics, Inc. This modification aims to expand the scope of the contract to include access to de-identified antibody results from previously tested specimens, focusing on individuals with immunocompromising conditions as part of the CDC's Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) Study. The contract modification is crucial for estimating the prevalence of SARS-CoV-2 infections and vaccinations across various demographics and geographic locations, utilizing existing data rather than incurring additional costs for new specimen collection. Interested parties may submit responses to this notice within 15 days to the primary contact, Liz Cole-Greenblatt, at qst7@cdc.gov, although the government retains discretion over whether to pursue competitive procurement.
    Single-Nuclei Multiome Analysis of Human Brain Tissue, iPSC-Derived Cells and Human Dorsal Root Ganglion
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified entities to conduct a Single-Nuclei Multiome Analysis of Human Brain Tissue, iPSC-Derived Cells, and Human Dorsal Root Ganglion. This procurement aims to advance research in medical laboratory testing by analyzing complex biological samples to enhance understanding of neurological conditions. The work is critical for developing innovative treatments and therapies in the field of neuroscience. Interested parties can reach out to Maggie Brant at maggie.brant@nih.gov or KJ Shaikh at KJ.Shaikh@nih.gov for further details regarding this opportunity.
    Newborn Screening Services- Notice of Intent to Sole Source
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award three sole source contracts for Newborn Screening Services, specifically targeting the provision of screening for up to 38 core conditions and 26 secondary conditions, along with specialty physician consultations for diagnosed newborns. The contracts will be awarded to the Newborn Screening Programs of the Florida, North Carolina, and Virginia Departments of Health, which will support Military Treatment Facilities in their respective states, ensuring timely medical interventions for newborns identified with certain genetic and metabolic conditions. This initiative is critical for early detection and treatment, which can prevent severe health issues in infants. Interested parties must submit capability statements by 12:00 PM EST on January 6, 2026, to the designated contacts, Brittany Belsches and Mary Shifflett, via email, as no competitive proposals will be solicited.
    Sole Source Notice - Development and Maintenance of an Aged Rodent Tissue Bank
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source modification to the University of Washington for the development and maintenance of an Aged Rodent Tissue Bank (ARTB). This modification aims to extend the contract period by 12 months, allowing for the continued collection, storage, and distribution of biospecimens from aged rodent colonies, which is critical for supporting the National Institute on Aging's mission. The services provided under this contract are essential for ongoing research and development in health-related fields, ensuring that there is no interruption in these vital services. Interested parties may express their interest and capability to fulfill this requirement within 30 days of this notice, and should direct inquiries to Robert Bailey at rob.bailey@nih.gov or Brian O'Laughlin at olaughlinb@nida.nih.gov.
    NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00017 WITH THE EMMES COMPANY, LLC.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source modification under Contract No. 75N95022D00017 to The Emmes Company, LLC, increasing the contract value by $13,158,436 to a total of $44,313,082. This modification aims to ensure the continuation of critical support services for ongoing and upcoming clinical trials related to substance use disorders, particularly in response to the national opioid crisis. The contract encompasses a range of services, including the establishment of secure data management systems, clinical trial design and analysis, and quality monitoring of study data. Interested parties may submit capability statements or objections to the proposed modification by December 30, 2025, to the primary contact, Llakim Dubroff, at llakim.dubroff@nih.gov.
    Biospecimen Core Resource
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) under the National Cancer Institute (NCI), is seeking to establish a Biospecimen Core Resource (BCR) to support various biospecimen-related activities. The BCR will operate under documented Standard Operating Procedures (SOPs) to facilitate the collection, processing, distribution, and storage of biospecimens as outlined in NCI Task Orders. This initiative is crucial for advancing cancer research and ensuring the integrity and availability of biospecimens for scientific studies. Interested parties can reach out to Apisit Viriya at apisit.viriya@nih.gov or Mataya Robinson at mataya.robinson@nih.gov for further details regarding this opportunity.
    Agilent Fragment Analyzer (96 capillary) and Femto pulse instruments
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is planning to award a sole source firm fixed price maintenance contract to Agilent Technologies for the preventative and remedial maintenance of the Agilent Fragment Analyzer (96 capillary) and Femto pulse instruments used in the Biotechnology Core Facility Branch. This contract aims to ensure compliance with the Quality Management System (QMS) requirements, highlighting the critical role these instruments play in ongoing research and development in biotechnology. The anticipated period of performance for this contract is from February 2, 2026, to February 1, 2027, with two optional one-year extensions available. Interested vendors are encouraged to express their interest and capability by submitting proposals to the Contracting Officer at uex0@cdc.gov by 5:00 PM (ET) on December 31, 2025.
    AN41--Research Core Facility Access to High-Throughput Genomics and Cancer Bioinformatics Pre-solicitation Notice with Intent to Sole Source
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to award a sole source contract to the University of Utah, Huntsman Cancer Institute (HCI), for specialized research services in high-throughput genomics and cancer bioinformatics. This five-year contract, valued at approximately $4,000,000, will support ongoing research programs at the Salt Lake City VA Medical Center, leveraging HCI's unique expertise and established relationship with the VA. The services provided are critical for advancing cancer research and treatment, and due to the specific requirements and ongoing projects, HCI is deemed the only capable provider. Interested parties may contact Contracting Officer Ann Marie Stewart at annmarie.stewart@va.gov by December 30, 2025, to express interest, although the decision for a competitive procurement remains at the discretion of the Contracting Officer.